Abstract CT064: Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Authors: Bilal A. Siddiqui, Jingsong Zhang, Benedito A. Carneiro, Kevin K. Zarrabi, Mark N. Stein, David R. Wise, Edward P. Gelmann, Che-Kai Tsao, Gerald Falchook, Joseph W. Kim, Xin Gao, Przemyslaw W. Twardowski, Divya Rana, Fang Fang, Shilpa Govindraj, Jennifer S. Sims, Dimitris Skokos, Frank A. Seebach, Israel Lowy, Pradeep Thanigaimani, Matthew Ingham, Sabina Sandigursky, Elizabeth Miller

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-ct064

Source: Full article